How I Overcame My 50-Year Struggle With Gynecomastia

Before we get started, here's a little story from one of my clients, Sammie Fields.
Hey there I’m Sammie.

I’m in my 70s now and I’m finally enjoying my life as a masculine-looking guy. I struggled with gynecomastia ever since puberty. Back in the day it was totally unheard of for a man to have breasts.

Man boobs were quite a rare thing. If you think having man boobs is bad now, try having them in the 60s. I spent my entire life in fear that someone would notice my breasts. I stayed away from women - I was horrified of the bedroom. I also stayed away from the beach and only got out wearing the thickest of clothing to try and conceal myself.

Back then there was no internet, and no information out there to help me. I tried everything I could to try and get rid of my man boobs. I lost weight and tried different diets but all to no avail.

One day however, just a few years ago I came across a newspaper article.

This article complained of how male fish in our waters were becoming feminized. Scientists had studied these male fish and found how they had developed feminine characteristics, even to the point of producing eggs! Apparently this was due to the prevalence of the female hormone estrogen in our water supply.

Apparently, due to most government water filtration systems (including the US), estrogen passes unfiltered right into our taps, and straight into your belly when you drink that glass of water.

The estrogen is being absorbed by us and is resulting in modern man having low sperm counts, fertility problems and gynecomastia. Heck it might even be responsible for the boom in the male cosmetics industry (joke).

So I went out there, did some research and found some other shocking sources of estrogen that exist especially in the modern environment, but were also there in the past albeit in much lower quantities and not as widespread back in the day.

Why am I telling you all this?

Well I lost my man boobs in my mid-sixties. The only way I managed to succeed was after I armed myself with the facts, and all the information I needed to know about the very root cause of my gynecomastia.

If I could get rid of my gynecomastia in my sixties, then I know for a fact that anyone else can do it too. So if you're about to give up or you have given up and are ready to face the world as a pseudo-man, then I'm here to tell you to wake up! Get out of that trance, shake yourself up and inform yourself of real working tactics that have been proven time and time again to help many thousands of guys lose their man boobs permanently using all-natural methods.

And I can't think of a better person to help you than my good friend Robert Hull. I leave you to his very capable hands and I'm sure that you will learn much on his new blog.

Tuesday, May 3, 2011

Agile Therapeutics AG200-15 Contraceptive Patch Shows Hormonal Exposure Similar To Low-Dose Oral Contraceptives In Phase II Data


Main Category: Women's Health / Gynecology
Also Included In: Clinical Trials / Drug Trials
Article Date: 03 May 2011 - 8:00 PDT email icon email to a friend � printer icon printer friendly � write icon opinions �

Current Article Ratings:


Patient / Public: not yet rated
Healthcare Prof: not yet rated

Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women's contraceptive products, today announced the presentation and publication of three studies highlighting Phase II data with AG200-15, the company's combination hormonal contraceptive patch. The definitive pharmacokinetic study demonstrated that AG200-15 delivers a daily estrogen (ethinyl estradiol) dose of 30ug, comparable to low-dose oral contraceptives. The studies also reported the safety and tolerability profile of AG200-15 in addition to data on ovulation in obese and non-obese women. Two abstracts were presented at the American College of Obstetricians and Gynecologists' 59th Annual Clinical Meeting (ACM) taking place in Washington, DC, from April 30th through May 4th. Data has also been published in the April 2011 volume of Hormone Molecular Biology and Clinical Investigation.

"These studies demonstrate that our contraceptive patch (AG200-15) is delivering a low dose of ethinyl estradiol, as well as a dose of levonorgestrel that is consistent with the efficacy and safety profile of low-dose oral contraceptives," said Marie Foegh, M.D., Dr.Sc., Chief Medical Officer, Vice President, Clinical Research and Development, Agile Therapeutics. "The results of these studies supported our decision to initiate our Phase III program, which has enrolled over 2,000 women and will provide the basis for an application to the US Food and Drug Administration. Our Phase III program population is reflective of the US population, including women across a wide range of body mass index (BMI)".

Two abstracts presented today at the American College of Obstetricians and Gynecologists' ACM highlight data from Phase II studies evaluating the safety, tolerability and pharmacokinetic profile of AG200-15. The first abstract is a study conducted in thirty-six healthy women to establish the pharmacokinetic profile of ethinyl estradiol (EE) and levonogrestrel (LNG) in AG200-15, and to compare the EE exposure with the AG200-15 contraceptive patch to a low-dose oral contraceptive. The EE exposure was lower in those women using the AG200-15 patch versus the low-dose oral contraceptive. The calculated daily dose of AG200-15 was equivalent to 30 �g of EE. AG200-15 was found to be generally safe and well tolerated.

The second abstract presented an evaluation of ovarian suppression in obese versus non-obese women enrolled in the AG200-15 Phase II multicenter clinical study. AG200-15 was evaluated in thirty-three women with BMI ranging from 17-52 kg/m2; 24% of subjects were considered obese (BMI -30kg/m2). Serum progesterone was measured twice weekly as an indicator of ovarian suppression, and study authors observed a trend of higher serum progesterone levels during week one of treatment cycles two and three in the obese population. No difference in ovulation was reported between obese and non-obese women. Researchers suggested that there is likelihood that ovarian activity (luteinization) may be more frequent in obese women using the AG200-15 patch. Phase III studies are currently underway to further assess the efficacy of the AG200-15 patch in women of various weights, including subjects with BMI > 30 and BMI > 35 kg/m2, with study completion on schedule for late 2011. The Agile Phase III study is fairly unique for contraceptive studies in that women with high BMI were not excluded.

In addition to the data presented at the ACM, Agile Therapeutics also announced the publication of data from two Phase II studies to evaluate the pharmacokinetic profile, cycle control, safety and tolerability of three transdermal contraceptive delivery systems. The study, "Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel," by lead author Frank Z. Stanczyk, Ph.D. Professor of Research, Departments of Obstetrics and Gynecology and Preventive Medicine, Keck School of Medicine, University of Southern California, appears in Hormone Molecular Biology and Clinical Investigation, a peer-review journal dedicated to providing data on molecular aspects of hormones in physiology and in pathophysiology.

The results of these studies supported the further testing of the AG200-15 contraceptive patch in Phase III contraceptive efficacy and safety studies, which will be completed this year.

The studies described above were supported by Agile Therapeutics, Inc.

Source:
Agile Therapeutics

Please rate this article:
(Hover over the stars
then click to rate)		 Patient / Public:
 or Health Professional:
Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:




Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd � 2004-2011 All rights reserved.


Source: http://www.medicalnewstoday.com/articles/224052.php

women health and fitness womens health health women womens issues

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)